Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a portable ultrasound scan replace costly scans for muscle loss?

NCT ID NCT07836088

Diagnosis Sponsor: Zhangzhou Municipal Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time

Summary

Researchers are testing whether a non-invasive ultrasound technique can accurately measure muscle mass in people with metabolic syndrome, type 2 diabetes, and obesity. The study enrolls 320 participants, including healthy controls, and compares ultrasound measurements against DXA scans, the current reference standard. Participants also undergo blood tests and muscle function tests, and those with metabolic conditions are followed for 12 months to see whether ultrasound findings relate to disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
multimodal ultrasound imaging, a non-invasive scan combining B-mode imaging, shear-wave elastography, superb microvascular imaging, and artificial intelligence analysis
What this could lead to
If it works, doctors could use a portable, radiation-free scan to spot muscle loss early in people with metabolic conditions and track how their disease changes over time.
What could go wrong
This is an observational study, so it cannot prove that ultrasound improves health outcomes. Ultrasound readings can vary between operators and machines, and the results may not hold up in other clinics or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with metabolic syndrome, type 2 diabetes, or simple obesity, as well as healthy volunteers, recruited from the Endocrinology Department and Physical Examination Center of Zhangzhou Hospital, Fujian Medical University. All participants must meet the specified inclusion and exclusion criteria. The three metabolic disease groups will be matched with healthy controls by age and sex. A total of 320 participants (80 per group) will be enrolled.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of metabolic syndrome according to the Chinese Consensus on Diagnosis and Management of Metabolic Syndrome (2020 edition), meeting at least 3 of the following 5 criteria: abdominal obesity, hypertension, hyperglycemia, hypertriglyceridemia, and low HDL-C. * Diagnosis of type 2 diabetes according to the ADA 2023 diagnostic criteria, with disease duration of at least 1 year. * Body mass index (BMI) \>= 28 kg/m², without hypertension, hyperglycemia, dyslipidemia, or other metabolic abnormalities. * Healthy volunteers without metabolic diseases, muscle diseases, chronic liver or kidney dysfunction, malignancies, cardiovascular diseases, or neurological disorders, and without long-term use of corticosteroids or other medications affecting muscle metabolism. * Age and sex matched across all four groups. * Willing and able to provide written informed consent and comply with all study procedures including ultrasound examination, DXA scan, and follow-up visits. Exclusion Criteria: * Severe hepatic or renal failure, malignancy, stroke, severe cardiovascular disease, or autoimmune diseases. * Long-term use of corticosteroids, muscle relaxants, or other medications affecting muscle metabolism. * Presence of movement disorders, joint diseases, muscle injury, muscular dystrophy, or other conditions affecting muscle function. * Pregnancy or lactation. * Inability to cooperate with ultrasound examination, DXA scanning, or follow-up assessments. * Any other condition that, in the opinion of the investigator, would interfere with the study objectives or participant safety.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Insulin Resistance metabolic syndrome X Obesity obesity disorder Sarcopenia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic syndrome Obesity Sarcopenia Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhangzhou Hospital, Fujian Medical University

    RECRUITING

    Zhangzhou, Fujian, 363000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.